GlobeNewswire

Polk County Mosquito Control Reduces Aedes aegypti by Up to 95% with Sterile Insect Farms™ Sterile Male Releases
30/10/2026
BUFORD, Ga., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Polk County Mosquito Control has reduced populations of Aedes aegypti (its top problem species and a primary carrier of dengue, Zika, and chikungunya) by up to 95% after [...]
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
30/10/2026
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technology Technologies will be presented at TCT 2026 in the Canon booth TUSTIN, Calif. and ST. LOUIS, [...]
Aer Therapeutics Announces Top-Line Results from its Phase 2a Proof-of-Concept Trial of Fexlamose in Chronic Obstructive Pulmonary Disease (“COPD”)
30/10/2026
90 mg dose of fexlamose administered daily via nebulizer did not demonstrate improvement on trough FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not [...]
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
30/10/2026
Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27 Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 [...]
Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
30/10/2026
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical’s Copernicus™ program, expanding Profound’s commercial reach Profound retains direct TULSA-PRO recurring treatment kit [...]
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
30/10/2026
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling [...]
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
30/10/2026
- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the [...]
Halloween Peptide Sale 2026: Kylo Peptides Announces $1 Research Vial Sale With Orders of $200 or More
30/10/2026
SHERIDAN, Wyo., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a U.S. research peptides supplier, today announced a limited-time Halloween sale. Customers who place an order of $200 or [...]
Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
30/10/2026
The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991). 1 AIRWARD will evaluate the efficacy and safety of verducatib, an investigational oral therapy for COPD. 1 The Phase III trial will [...]
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
30/10/2026
First FDA-approved biologic specifically designed to cross blood-brain barrier wins award dedicated to exceptional scientific leadership and transformational impact on patient care First new FDA-approved treatment [...]
Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace
30/10/2026
An Equipment Innovator’s Interest in Kraig’s High Tech Fibers Indicates Potential Applications for Lightweight and/or Tough Materials, and Possibly Elevate Project Atlas DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( www. [...]
NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
30/10/2026
500 Patients, 30 Hospitals, 3 Countries is Part of the Setup DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com ) — In a market where the latest whizbang trends often dominate investor attention, NeOnc [...]
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
30/10/2026
Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary [...]
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
30/10/2026
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to discuss [...]
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
30/10/2026
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax [...]
Press Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026
30/10/2026
PRESS RELEASE, October 30, 2026 – 08:00 CDT Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026 ITASCA, IL, US – October 30, 2026. Today, Biocartis , an innovative [...]
Femasys Appoints John Moorhead to Board of Directors
30/10/2026
ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the [...]
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
30/10/2026
Redesigned site brings together information on BGLC’s operating businesses, healthcare initiatives and public disclosures KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC [...]
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
30/10/2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum